Erythromycin C (CAS 1675-02-1)

Erythromycin C, a member of the macrolide antibiotic family, has been a subject of considerable scientific interest due to its unique mechanism of action and versatile research applications. Mechanistically, erythromycin C inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit of bacteria, thereby blocking the translocation of peptidyl-tRNA from the A-site to the P-site during translation. This interference disrupts the elongation of the peptide chain, leading to the inhibition of bacterial growth. Erythromycin C′s mechanism of action makes it effective against a broad spectrum of gram-positive bacteria, including strains resistant to other antibiotics. In research, erythromycin C has been invaluable for elucidating the structural and functional properties of the bacterial ribosome, providing insights into the molecular basis of antibiotic activity and bacterial resistance mechanisms. Moreover, erythromycin C has been used as a tool in molecular biology and cell biology research, particularly in studies involving bacterial translation, gene expression, and protein synthesis. Additionally, erythromycin C and its derivatives have been explored for their potential applications in biotechnology, such as in the production of recombinant proteins and the development of novel antimicrobial agents. Ongoing research continues to explore the diverse research applications of erythromycin C, offering promising avenues for understanding bacterial physiology and combating antibiotic resistance.